The European Medicines Agency has accepted Pfizer's regulatory submissions for review of two investigational compounds.One of them,crizotinib,targets a form of advanced non-small cell lung cancer(NSCLC);the other,bosutinib,is aimed at newly diagnosed chronic myeloid leukemia.Both compounds are believed to inhibit signaling in cancer cells that allows them to grow,survive and reproduce.
Pfizer Oncology says its pipeline is focused on identifying and translating the best scientific breakthroughs into clinical applications across a wide range of cancers.It has biologics and small molecules in clinical development and more than 100 clinical trials underway.
With its wide array of research partners,ranging from individual researchers to academic institutions,Pfizer Oncology strives to deliver the right drug for each patient at the right time to cure or control cancer.
Pfizer is listed on the London and New York stock exchanges under the ticker symbols PFZ and PFE,respectively.CEO Ian Read heads the New York-based company.
No comments:
Post a Comment